CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
LY2886721drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01367262
NCT01367262Phase 1Completed
CompareCT.gov

Disposition of [14C]-LY2886721 Following Oral Administration in Healthy Human Subjects

Eli Lilly and Company·interventional·Posted Jun 7, 2011·Updated Sep 13, 2019

In Brief

A Phase 1 clinical trial evaluating LY2886721 for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This open-label study is being conducted to determine the metabolism and physiological disposition of radiolabeled LY2886721 after a single dose in healthy male participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 7, 2011
Enrollment StartJun 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 15.1 years ago

Interventions

LY2886721drug

Administered orally